WFDC2 and lung adenocarcinoma: Although previous work on HE4 has primarily focused on its clinical utility as a tumor biomarker, increasing evidence has suggested that HE4 may have diagnostic potential in other clinical settings, including lung adenocarcinomas (18), renal fibrosis (8) and cystic fibrosis (9).